ARSEUS (D) : Disclosure of acquisition of treasury shares

Press Release

Regulated information

DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)1, 2 January 2013- Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 20 December 2012 to 2 January 2013, it acquired 15,201 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with
a discretionary mandate).

Number of Average Lowest Highest Acquisition date Amount shares price price price
20 December 2012	4,194	€ 15.1697	€ 15.12	€ 15.28	€ 63,622
21 December 2012	4,673	€ 15.0266	€ 14.87	€ 15.12	€ 70,219
24 December 2012	1,856	€ 15.3113	€ 15.28	€ 15.33	€ 28,418
27 December 2012	3,202	€ 15.3090	€ 15.28	€ 15.37	€ 49,019
28 December 2012	1,178	€ 15.3866	€ 15.37	€ 15.39	€ 18,125
31 December 2012	98	€ 15.4500	€ 15.45	€ 15.45	€ 1,514

Further, on 21 December 2012 Arseus acquired 25,327 shares via a block trade for a price per share of € 15.10, i.e. in total € 382,438.
The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the
Board of Directors to acquire treasury shares.
Prior to the transactions, Arseus already held 611,247 treasury shares. As a result of the transactions referred to above, Arseus now holds 651,775 treasury shares, representing 2.08% of
the total number of shares outstanding.

1 This press release was sent out by Arseus NV and Arseus BV.

1/2

For more information:

Constantijn van Rietschoten
Director of Corporate Communications
[phone] (Office)
[phone] (Mobile)
[e-mail]
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 28 countries in Europe, North America, South America, Asia and Australia. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of

Arseus BV is located in Rotterdam.
2/2